News

A new study investigated the differences in the services provided to patients with chronic obstructive pulmonary disease (COPD) by doctors and by nurse practitioners and physician assistants. The study was conducted by researchers from The University of Texas Medical Branch (UTMB) at Galveston, and published in the scientific periodical PLOS…

Physical activity undertaken in small intervals spaced throughout the day can safely and markedly improve the health of people with chronic obstructive pulmonary disease (COPD) and other lung ailments, researchers in Australia reported, based on a review of COPD studies. Dr. Kylie Hill from the Curtin University led the research project,…

Propeller Health has partnered with Aptar Pharma, a drug delivery systems provider, for the development of technology based on metered dose inhaler systems (MDIs) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Under the terms of the partnership, Propeller and Aptar will work to develop the…

A recent study examined the possible association between more frequent exacerbations in chronic obstructive pulmonary disease (COPD) and stroke, finding no evidence for such a link. The report, “No association between exacerbation frequency and stroke in patients with COPD,“ appeared on Feb. 2, 2016, in the…

A study recently published in the journal Chest found that patients with chronic obstructive pulmonary disease (COPD) had decreased gray matter in cerebral areas that process breathlessness, fear, and pain sensitivity. Intrapulmonary inflammatory processes restrict the flow of air in the lungs of people with COPD, and breathlessness is commonly experienced…

Boehringer Ingelheim Pharmaceuticals, Inc., recently released data showing that Stiolto Respimat (inhalation spray) improved lung function over a range of measures in patients with chronic obstructive pulmonary disease (COPD), when compared to a European formulation of a long-acting beta agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate). Stiolto Respimat was approved…

Lexington, Massachusetts-based Pulmatrix Inc. is enrolling participants for a European pilot bioequivalence study on its product PUR0200, a bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD). The company expects to finish enrollment by the first quarter of 2016 and report initial results in the second quarter. Pulmatrix says its iSPERSE (inhaled…

In a new study, researchers at the University of Toronto investigated the independent relationship between chronic obstructive pulmonary disorder (COPD) and past-year generalized anxiety disorder (GAD), and found that the prevalence of anxiety is much higher among older adults with COPD than in older adults without the disease. The…

Researchers discovered that patients with chronic obstructive pulmonary disease (COPD) show increased levels of a protein that inhibits the immune system response against several pathogens, thereby increasing their vulnerability to infections. The study, “Osteopontin That Is Elevated in the Airways during COPD Impairs the Antibacterial Activity of Common Innate…

Researchers at the Lung Institute detailed the benefits of autologous stem cell therapy in people with chronic obstructive pulmonary disease (COPD), through an analysis of the treatment’s effects in one of the largest cohorts of these patients. The white paper, authored by Dr. Jack Coleman Jr., MD, was titled “Autologous Stem…